Evvy Secures $40M Series B Led by Catalio to Scale Vaginal Microbiome Research

Evvy Closes $40M Series B Round

In a notable milestone for the femtech and healthcare sectors, women’s health company Evvy announced a $40 million Series B funding round. The financing was led by Catalio Capital Management, signaling strong institutional backing for data-driven approaches to female biology. The fresh capital will be deployed to accelerate research and development initiatives, focusing specifically on scaling the collection and analysis of vaginal microbiome data.

Strategic Focus on Vaginal Microbiome Research

For decades, the vaginal microbiome has remained an under-researched area within mainstream clinical medicine, despite its profound impact on overall health, reproductive outcomes, and systemic wellness. Evvy aims to bridge this critical data gap. By combining direct-to-consumer testing with advanced bioinformatics, the company builds robust proprietary datasets designed to decode the complexities of the female microbiome. This funding will allow Evvy to expand its clinical studies, refine its platform, and establish clearer links between microbial signatures and targeted health interventions.

Market Implications for Femtech and Venture Capital

The successful closure of a $40 million Series B in a selective economic environment demonstrates sustained investor confidence in high-impact women’s health enterprises. Key market implications include:

• Validation of Femtech Infrastructure: Investors are increasingly prioritizing companies that build proprietary data moats rather than mere consumer products.
• Shift Toward Precision Medicine: The integration of microbiome analytics paves the way for personalized therapeutics and diagnostics in gynecology and beyond.
• Capital Concentration: Institutional funds like Catalio Capital Management are steering larger, later-stage checks into category-defining leaders that exhibit clear clinical and commercial synergy.

Key Trends and Metrics to Watch

As Evvy deploys its $40 million Series B capital, executives, investors, and entrepreneurs should closely monitor several strategic indicators:

• Clinical Partnerships: Expansion of academic and pharmaceutical collaborations leveraging Evvy’s proprietary microbiome database.
• Regulatory Milestones: Potential shifts toward FDA-cleared diagnostics or therapeutics derived from large-scale microbiome insights.
• Competitive Landscape: How other venture-backed players in women’s health respond to the increasing emphasis on proprietary biological data.

For more details on the original announcement, readers can verify the report directly at the TechCrunch Coverage.